NCT01409499

Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

A Prospective Multicenter Non-randomized Controlled Study of Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy or TACE. The study is to investigate whether the active treatment will profit survival of patients, and to evaluate the safety.

Detailed description

This is a prospective non-randomized controlled study. Patients with advanced hepatocellular carcinoma (BCLC C stage) who underwent palliative resection or TACE followed with Sorafenib or treated by sorafenib alone will be included. The patients will be divided to group A (palliative resection plus sorafenib), group B (palliative TACE plus sorafenib), and group C (sorafenib alone). The sample size will be about 200 cases altogether.

Conditions

• Hepatectomy
• Hepatocellular Carcinoma
• Sorafenib

Interventions

Type	Name	Description
PROCEDURE	hepatic resection	palliative hepatectomy followed by sorafenib
PROCEDURE	transcatheter hepatic arterial chemoembolization	TACE followed by sorafenib
DRUG	sorafenib	sorafenib monotherapy, 400mg Bid, continuously

Timeline

• Start date: 2011-01-01
• Primary completion: 2017-06-01
• Completion: 2018-01-01
• First posted: 2011-08-04
• Last updated: 2018-09-11

Locations

1 site across 1 country: China